Detailed Information

Cited 16 time in webofscience Cited 17 time in scopus
Metadata Downloads

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis

Authors
Hong, Jung YongYoon, Dok HyunSuh, CheolwonKim, Won SeogKim, Seok JinJo, Jae-CheolKim, Jin SeokLee, Won-SikOh, Sung YongPark, YongKim, Sung-YongLee, Mark HongLee, Ho SupDo, Young Rok
Issue Date
Aug-2018
Publisher
SPRINGER
Keywords
Bendamustine; Rituximab; Diffuse large B cell lymphoma
Citation
ANNALS OF HEMATOLOGY, v.97, no.8, pp 1437 - 1443
Pages
7
Indexed
SCI
SCIE
SCOPUS
Journal Title
ANNALS OF HEMATOLOGY
Volume
97
Number
8
Start Page
1437
End Page
1443
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/3311
DOI
10.1007/s00277-018-3317-6
ISSN
0939-5555
1432-0584
Abstract
Bendamustine plus rituximab (BR) showed efficacy and safety in indolent lymphomas and mantle cell lymphoma. However, there were limited experiences of real-world practice of BR in diffuse large B cell lymphoma (DLBCL). In this study, we report the Korean experiences with BR in relapsed or refractory DLBCL who are not eligible for intensive chemotherapy and autologous stem cell transplantation. This is an observational, multicenter, retrospective analysis. Between December 2011 and December 2015, a total of 58 patients with relapsed or refractory DLBCL were treated with BR in 11 tertiary hospitals in Korea. Patients received an intravenous (IV) infusion of rituximab at a dose of 375 mg/m(2) on day 1. On days 2 and 3, patients received an IV infusion of bendamustine at doses of 120 or 90 mg/m(2). Median age was 69 (range 18-86), 74.1% had stage III or IV disease, and 67.2% showed high-intermediate or high International Prognostic Index scores at diagnosis. In an intention-to-treat analysis, 18 patients (31.0%) showed a complete response and 14 (24.1%) showed a partial response, resulting in an overall response rate of 55.1%. The median duration of the response was 3.7 months (range 1.0-47.2 months). The median progression-free survival was 3.9 months (95% confidence interval [CI], 2.4-5.4 months), and the median overall survival was 6.7 months (95% CI, 4.7-8.7 months). The most common grade 3/4 adverse event was neutropenia (n = 40; 68.9%). Febrile neutropenia was observed in 11 patients (18.9%). Grade 3/4 thrombocytopenia was observed in 34 patients (58.6%). Our study confirmed the high efficacy and acceptable toxicity profile of BR in relapsed or refractory DLBCL patients. However, we need to closely observe the higher tendency of grade 3/4 hematological toxicities in Korean patients.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Yong photo

Park, Yong
Anam Hospital (Department of Medical Oncology and Hematology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE